1. Loser: Daiichi Sankyo

Company: Daiichi Sankyo
Symbol: $JP:4568
Beginning Price: 1524 yen
Ending Price: 1254 yen
Loss: 17.72%

If Daiichi Sankyo's top-level management are frustrated, you can't blame them. As 2012 began, the company dispatched a Japanese posse to oversee manufacturing at its troubled Indian subsidiary, Ranbaxy Laboratories. Then, the company announced Ranbaxy's precedent-setting consent decree with the FDA, which included a $500 million charge. That took its toll on the Indian company's bottom line--and, like Ranbaxy's other losses, caused a ripple effect at the parent company the following quarter. Meanwhile, the company's Effient blood thinner failed to best rival Plavix, now generic, in a clinical trial. An oncology partnership with ArQule ($ARQL) hit rocky ground as a lung cancer drug failed a late-stage trial. And as the yen lost ground against the dollar, currency losses helped undercut net income for the first 6 months of its fiscal year. The company's good news--including modest year-over-year sales growth and a new vaccine alliance with GlaxoSmithKline ($GSK)--was capped off by another fiasco at Ranbaxy. The Indian company had to recall its copy of Pfizer's ($PFE) cholesterol drug Lipitor, the drug that had helped redeem Ranbaxy in Daiichi's books, in late November.

For more:
Daiichi Sankyo opens first U.S. manufacturing plant
Ranbaxy CEO to ride out transformation under DOJ oversight

 

1. Loser: Daiichi Sankyo
Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.